Kodiak Sciences Inc.
KOD
株式のランク
#3071
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
株価
$93.69
時価総額
$5.89B
変化（1日）
2.56%
変化（1年）
429.32%
国
US
取引 Kodiak Sciences Inc. (KOD)
カテゴリー
Healthcare
Kodiak Sciences Inc.（KOD）の利益
Jun 2026 時点の利益 TTM: $-241.99M
Kodiak Sciences Inc. の最新の財務報告によると、同社の現在の利益は $-241.99M です。2023 年には $-260.49M の利益を上げ、これは 2022 年の利益 $-333.82M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Kodiak Sciences Inc. の利益の推移（2016 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-241.99M | 37.34% |
| 2024 | $-176.21M | -32.36% |
| 2023 | $-260.49M | -21.97% |
| 2022 | $-333.82M | 25.03% |
| 2021 | $-266.99M | 100.60% |
| 2020 | $-133.10M | 181.00% |
| 2019 | $-47.37M | 14.29% |
| 2018 | $-41.44M | 48.35% |
| 2017 | $-27.94M | 63.06% |
| 2016 | $-17.13M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -2,279.76% |
US
|
|
| $-3.09B | 1,175.65% |
US
|
|
| $-4.02B | 1,559.63% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -906.07% |
NL
|
